MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

20.47 -1.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.19

Max

21.16

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

16.25

90.422

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-11.85% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

321M

1.1B

Vorige openingsprijs

22.1

Vorige sluitingsprijs

20.47

Nieuwssentiment

By Acuity

50%

50%

148 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 jan 2026, 23:07 UTC

Winsten

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 jan 2026, 21:27 UTC

Winsten

Texas Instruments 4Q Sales Rise, Profit Falls

27 jan 2026, 23:55 UTC

Marktinformatie

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 jan 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 jan 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 jan 2026, 23:39 UTC

Marktinformatie

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 jan 2026, 23:20 UTC

Winsten

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 jan 2026, 23:20 UTC

Winsten

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 jan 2026, 23:19 UTC

Winsten

SK Innovation Posts Net Loss for Second Consecutive Year

27 jan 2026, 23:19 UTC

Winsten

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 jan 2026, 23:18 UTC

Winsten

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 jan 2026, 23:18 UTC

Winsten

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 jan 2026, 23:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 jan 2026, 23:11 UTC

Marktinformatie

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 jan 2026, 23:07 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 jan 2026, 22:17 UTC

Marktinformatie

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 jan 2026, 22:06 UTC

Winsten

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 jan 2026, 21:51 UTC

Winsten

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 jan 2026, 21:43 UTC

Winsten

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 jan 2026, 21:41 UTC

Winsten

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 jan 2026, 21:38 UTC

Winsten

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 jan 2026, 21:32 UTC

Winsten

Ampol: Modest Profit From F&I International in 2025

27 jan 2026, 21:32 UTC

Winsten

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 jan 2026, 21:31 UTC

Winsten

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 jan 2026, 21:31 UTC

Winsten

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 jan 2026, 21:30 UTC

Winsten

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 jan 2026, 21:29 UTC

Winsten

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 jan 2026, 21:29 UTC

Winsten

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 jan 2026, 21:28 UTC

Winsten

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-11.85% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -11.85%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

148 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat